{"entity":{"id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","aka":[],"tldr":"A phase 2 trial of PM8002, Pemetrexed, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07680764 by Bristol-Myers Squibb, with 160 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-09-15. Interventions recorded: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07680764","url":"https://clinicaltrials.gov/study/NCT07680764"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002","pemetrexed","cisplatin","carboplatin","paclitaxel"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07680764","phase":"2","setting":"A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT07680764","source":"https://clinicaltrials.gov/study/NCT07680764","fetchedAt":"2026-10-07T16:55:56.330Z","studySha256":"e799b24d0d78bc787e5c5bd1a9a414e22a53634f9db82411c7f8def55cd2eb9b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-02","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":160,"enrolmentType":"ESTIMATED","siteCount":73,"recruitingSiteCount":16,"countries":["Argentina","Australia","Brazil","Chile","China","France","Germany","Italy","Romania","Spain","United Kingdom","United States"]}],"started":"2026-08-31","startedType":"estimated","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07680764/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}